Servicios Personalizados
Revista
Articulo
Indicadores
Citado por SciELO
Accesos
Links relacionados
Similares en SciELO
Compartir
Gaceta médica de México
versión On-line ISSN 2696-1288versión impresa ISSN 0016-3813
Resumen
MARTINEZ-MIRANDA, Rafael et al. Ceftolozane/tazobactam and ceftazidime/avibactam antimicrobial activity against clinically relevant gram-negative bacilli isolated in Mexico. Gac. Méd. Méx [online]. 2020, vol.156, n.6, pp.604-609. Epub 27-Mayo-2021. ISSN 2696-1288. https://doi.org/10.24875/gmm.19005335.
Introduction:
There is limited information on the effectiveness of ceftolozane/tazobactam and ceftazidime/avibactam combinations on clinically relevant strains isolated in Mexico.
Objective:
To determine the antimicrobial profile of both antibiotic combinations in our community.
Method:
The present research study was prospective, descriptive and cross-sectional. Clinically relevant strains isolated from pure-strain cultures were included during the period from August 2018 to January 2019 in Mexicali, Baja California, Mexico.
Results:
74 enterobacteriaceae and 19 Pseudomonas aeruginosa strains were analyzed; the percentage of sensitivity of ceftazidime/avibactam was 100 % for enterobacteriaceae and 72.7 % for Pseudomonas aeruginosa; the percentage of sensitivity of ceftolozane/tazobactam for enterobacteriaceae was 90.5 % and 72.7 % for Pseudomonas aeruginosa.
Conclusions:
The ceftolozane/tazobactam and ceftazidime/avibactam combinations offer good antimicrobial sensitivity in vitro, both for ESBL-producing enterobacteriaceae and Pseudomonas aeruginosa. More data are required to assess clinical response in patients receiving these antibiotic combinations.
Palabras llave : Cephalosporins; Beta-lactamase inhibitors; Multi-drug resistance.